Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025)
Marker Therapeutics' (MRKR) quarterly EBITDA Margin came in at 170.74% in Q4 2025, up 75.0% year-over-year from 97.56% in Q4 2024, and up 1.48% quarter-over-quarter from 173.3% in Q3 2025.
Powered by 
Analysis
Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported EBITDA Margin for 9 consecutive years, with 170.74% the latest figure, recorded in Q4 2025.
- On a quarterly basis, EBITDA Margin rose 75.0% year-over-year to 170.74% in Q4 2025; TTM through Dec 2025 was 397.58%, a 24777.0% decrease from a year earlier, with the FY2025 full-year figure at 363.45%, down 19476.0% from the prior year.
- EBITDA Margin was 170.74% for Q4 2025 at Marker Therapeutics, up from 173.3% in the prior quarter.
- Over five years, EBITDA Margin peaked at 110.67% in Q4 2022 and troughed at 1420.14% in Q1 2025.
- A 4-year average of 484.8% and a median of 204.89% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin jumped 111762 bps in 2024 and tumbled 121525 bps in 2025, its largest moves.
- Over 4 years, EBITDA Margin stood at 110.67% in 2022, then tumbled by 1022 bps to 1242.22% in 2023, then jumped by 86 bps to 171.48% in 2024, then advanced by 0 bps to 170.74% in 2025.
- The last three EBITDA Margin figures came in at 170.74% (Q4 2025), 173.3% (Q3 2025), and 594.79% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -25,827.14% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 0.56% |
| 10 | Marker Therapeutics | 23.37 Mn | 11.44 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -170.74% |
| Sep 30, 2025 | -173.30% |
| Jun 30, 2025 | -594.79% |
| Mar 31, 2025 | -1,420.14% |
| Dec 31, 2024 | -171.48% |
| Sep 30, 2024 | -124.60% |
| Jun 30, 2024 | -115.40% |
| Mar 31, 2024 | -204.89% |
| Sep 30, 2023 | -1,242.22% |
| Jun 30, 2023 | -506.23% |
| Mar 31, 2023 | -172.38% |
| Dec 31, 2022 | -110.67% |
| Sep 30, 2022 | -582.90% |
| Jun 30, 2022 | -666.47% |
| Mar 31, 2022 | -1,015.71% |
| Dec 31, 2020 | -25,616.37% |
| Jun 30, 2020 | -1,361.99% |
| Dec 31, 2019 | -2,515.10% |
| Jun 30, 2018 | -2,268.90% |
| Sep 30, 2017 | -2,179.30% |